Evidence map›Paper›PMID 40724817›Full record

ArticleInternational journal of molecular sciences2025

Development of INER-PP-F11N as the Peptide-Radionuclide Conjugate Drug Against CCK2 Receptor-Overexpressing Tumors.

Ming-Cheng Chang, Chun-Tang Chen, Ping-Fang Chiang, I-Chung Tang, Cheng-Liang Peng, Yuh-Feng Wang, Yi-Jou Tai, Ying-Cheng Chiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ming-Cheng ChangDepartment of Isotope Application Research, National Atomic Research Institute, P.O. Box 3-27, Longtan, Taoyuan 325207, Taiwan.ORCID 0000-0002-8377-1796
Chun-Tang ChenDepartment of Isotope Application Research, National Atomic Research Institute, P.O. Box 3-27, Longtan, Taoyuan 325207, Taiwan.
Ping-Fang ChiangDepartment of Isotope Application Research, National Atomic Research Institute, P.O. Box 3-27, Longtan, Taoyuan 325207, Taiwan.
I-Chung TangDepartment of Isotope Application Research, National Atomic Research Institute, P.O. Box 3-27, Longtan, Taoyuan 325207, Taiwan.
Cheng-Liang PengDepartment of Isotope Application Research, National Atomic Research Institute, P.O. Box 3-27, Longtan, Taoyuan 325207, Taiwan.ORCID 0000-0001-7130-0260
Yuh-Feng WangDepartment of Nuclear Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan.ORCID 0000-0002-0403-0536
Yi-Jou TaiDepartment of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100226, Taiwan.
Ying-Cheng ChiangDepartment of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100226, Taiwan.ORCID 0000-0002-8958-5222

Funding

National Science and Technology Council MOST 111-3111-Y-042A-009, NSTC 112-2623-E-002-004 -NUTaipei Veterans General Hospital V114C-056
6 · The paper itself

Abstract

This work aimed to evaluate two albumin affinity structure-containing peptide-radionuclide conjugate drugs, INER-PP-F11N-1 and INER-PP-F11N-2, for the diagnosis/treatment of cholecystokinin receptor subtype 2 (CCK2R)-overexpressing cancers. We developed In-111- and Lu-177-labeled INER-PP-F11N radiopharmaceuticals and compared them with the current PP-F11N to investigate metabolic stability, biodistribution, SPECT/CT imaging, and therapeutic responses in CCK2R-expressing tumor xenograft mice. The metabolic stability of [

Indexed as

NeoplasmsPeptidesRadioisotopesRadiopharmaceuticalsReceptor, Cholecystokinin BAnimalsCell Line, TumorHumansIndium RadioisotopesLutetiumMiceMice, NudeSingle Photon Emission Computed Tomography Computed TomographyTissue DistributionXenograft Model Antitumor AssaysIndium-111Indium RadioisotopesLutetiumLutetium-177PeptidesRadioisotopesRadiopharmaceuticalsReceptor, Cholecystokinin BCCK2RINER-PP-F11Npeptide-radionuclide conjugate drugradiopharmaceutical agenttheragnostic

Identifiers

PMID40724817
PMCPMC12294753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.